Scholars@Duke
Journal cover image

Cost-effectiveness of homologous recombination defect testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer

Journal articles
Alvarez-Secord, A; Barnett, J; Ledermann, J; Peterson, B; Myers, E; Havrilesky, L
Published in: Gynecologic Oncology
March 2012
Published version (DOI) Publisher Link

Duke Scholars

Evan Robert Myers
Author Evan Robert Myers Obstetrics and Gynecology, Women's Community & Population He ...
Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecologic Oncology

DOI

10.1016/j.ygyno.2011.12.223

ISSN

0090-8258

Publication Date

March 2012

Volume

125

Start / End Page

S92 / S93

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3215 Reproductive medicine
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Alvarez-Secord, A., Barnett, J., Ledermann, J., Peterson, B., Myers, E., & Havrilesky, L. (2012). Cost-effectiveness of homologous recombination defect testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology, 125, S92–S93. https://doi.org/10.1016/j.ygyno.2011.12.223
Alvarez-Secord, A., J. Barnett, J. Ledermann, B. Peterson, E. Myers, and L. Havrilesky. “Cost-effectiveness of homologous recombination defect testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.” Gynecologic Oncology 125 (March 2012): S92–93. https://doi.org/10.1016/j.ygyno.2011.12.223.
Alvarez-Secord A, Barnett J, Ledermann J, Peterson B, Myers E, Havrilesky L. Cost-effectiveness of homologous recombination defect testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology. 2012 Mar;125:S92–3.
Alvarez-Secord, A., et al. “Cost-effectiveness of homologous recombination defect testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.” Gynecologic Oncology, vol. 125, Elsevier BV, Mar. 2012, pp. S92–93. Crossref, doi:10.1016/j.ygyno.2011.12.223.
Alvarez-Secord A, Barnett J, Ledermann J, Peterson B, Myers E, Havrilesky L. Cost-effectiveness of homologous recombination defect testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology. Elsevier BV; 2012 Mar;125:S92–S93.
Journal cover image

Published In

Gynecologic Oncology

DOI

10.1016/j.ygyno.2011.12.223

ISSN

0090-8258

Publication Date

March 2012

Volume

125

Start / End Page

S92 / S93

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3215 Reproductive medicine
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences